Synthesis and biological evaluation of C-5 methyl substituted 4-arylthio and 4-aryloxy-3-iodopyridin-2(1H)-one type anti-HIV agents

Journal of Medicinal Chemistry

Volumn 52, Issue 23, 2009, Pages 7473-7487

  Guillemont, Jérôme ^a   Benjahad, Abdellah ^b   Oumouch, Said ^b   Decrane, Laurence ^a   Palandjian, Patrice ^a   Vernier, Daniel ^a   Queguiner, Laurence ^a   Andries, Koen ^c   De Béthune, Marie Pierre ^d   Hertogs, Kurt ^d   Grierson, David S ^b   Nguyen, Chi Hung ^b  

^a Campus de Maigremont   (France)

^b CNRS   (France)

^c JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^d Virco BVBA   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

1 [4 (3,5 DIMETHYLPHENOXY)5 IODO 2 METHYL 6 OXO 1,6 DIHYDROPYRIDIN 3 YLMETHYL]PIPERIDIN 4 YLCARBAMATE; 3 (3,5 DIMETHYLPHENOXY) 5 (FURAN 2 YLMETHYLTHIOMETHYL) 3 IODO 6 METHYL PYRIDIN 2 (1H)ONE; 4 (3,5 DIMETHYLPHENOXY) 3 IODO 5 (2 METHOXY ETHOXYMETHYL) 5 METHYLPYRIDIN 2 (1H)ONE; 4 (3,5 DIMETHYLPHENOXY) 3 IODO 5 (THIOPHEN 2 YL METHOXYMETHYL) 6 METHYLPYRIDIN 2 (1H)ONE; 4 (3,5 DIMETHYLPHENOXY) 5 (2 HYDROXY ETHOXYMETHYL) 3 IODO 6 METHYLPYRIDIN 2 (1H)ONE; 4 (3,5 DIMETHYLPHENOXY) 5 (ETHANESULFONYLMETHYL) 3 IODO 6 METHYLPYRIDINE 2 (1H)ONE; 4 (3,5 DIMETHYLPHENOXY) 5 (FURAN 2 YLMETHYLTHIOMETHYL) 3 IODO 6 METHYL PYRIDIN 2(1H) ONE; 4 (3,5 DIMETHYLPHENOXY) 5 [N(FURAN 2 YLMETHYL)N METHYL]AMINOMETHYL 3 IODO 6 METHYLPYRIDINE 2 (1H)ONE; 4 (3,5 DIMETHYLPHENYLSULFANYL) 2 METHYL 6 OXO 1,6 DIHYDROPYRIDIN 3 YLCARBONITRILE; 4 (3,5 DIMETHYLPHENYLSULFANYL) 3 IODO 6 METHYL 5 (1H PYRROL 2 YLMETHYL)PYRIDIN 2 (1H)ONE; 4 (3,5 DIMETHYLPHENYLSULFANYL) 3 IODO 6 METHYL 5 (TETRAZOL YL METHYL)PYRIDIN 2(1H)ONE; 4 (3,5 DIMETHYLPHENYLSULFANYL) 3 IODO 6 METHYL 5 (TETRAZOL YLMETHYL)PYRIDIN 2(1H)ONE; 4 (3,5 DIMETHYLPHENYLSULFANYL) 3 IODO 6 METHYL 5 [3 METHYL(1,2,4)TRIAZOL 1 YLMETHYL)PYRIDIN 2 (1H)ONE; 4 (3,5 DIMETHYLPHENYLSULFANYL) 5 IODO 2 METHYL 6 OXO 1,6 DIHYDROPYRIDINE 3 YLCARBONITRILE; 4 CHLORO 2 METHYL 6 OXO 1,6 DIHYDROPYRIDIN 3YLCARBONITRILE; 5 CHLOROMETHYL 3 IODO 6 METHYL 4 (3,5 DIMETHYLPHENYLSULFANYL)PYRIDIN 2 (1H)ONE; 5 CHLOROMETHYL 6 METHYL 4 (3,5 DIMETHYLPHENYLSULFANYL)PYRIDIN 2 (1H) ONE; 5 ETHOXYMETHYL 3 IODO 6 METHYL 4 (3,5 DIMETHYLPHENOXY)PYRIDIN 2 (1H)ONE; 5 ETHOXYMETHYL 3 IODO 6 METHYL 4 (3,5 DIMETHYLPHENYLSULFANYL)PYRIDIN 2 (1H)ONE; 5 ETHOXYMETHYL 6 METHYL 4 (3,5 DIMETHYLPHENYLSULFANYL)PYRIDIN 2 (1H) ONE; 5 HYDROXYMETHYL 3 IODO 6 METHYL 4 (3,5 DIMETHYLPHENYLSULFANYL)PYRIDIN 2 (1H)ONE; 5 HYDROXYMETHYL 3 IODO 6 METHYL 4 (3,5 DIMETHYLPHENYLSULFANYL)PYRIDIN 2(1H) ONE; 5 HYDROXYMETHYL 5 METHYL 4 (3,5 DIMETHYLPHENYLSULFANYL)PYRIDIN 2 (1H)ONE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; EFAVIRENZ; ETHYL 4 (3,5 DIMETHYLPHENYLSULFANYL) 2 METHYL 6 OXO 1,6 DIHYDROPYRIDIN 3 YL CARBOXYLATE; ETHYL 4 (3,5 DIMETHYLPHEYLSULFANYL) 5 IODO 2 METHYL 6 OXO 1,6 DIHYDROPYRIDIN 3 YLCARBOXYLATE; ETHYL 4 CHLORO 2 METHYL 6 OXO 1,6 DIHYDROPYRIDIN 3YLCARBOXYLATE; NEVIRAPINE; PYRIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; ARTICLE; CONTROLLED STUDY; DRUG SCREENING; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IC 50; NONHUMAN; SUBSTITUTION REACTION; VIRUS INHIBITION; VIRUS MUTANT; VIRUS STRAIN; WILD TYPE;

ANTI-HIV AGENTS; CELL LINE; HIV; HIV REVERSE TRANSCRIPTASE; HUMANS; INHIBITORY CONCENTRATION 50; IODOPYRIDONES; MUTATION; SMALL MOLECULE LIBRARIES;

EID: 72249123164     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm900802y     Document Type: Article

References (32)

1. Lucas, G. M.; Chaisson, R. E.; Moore, R. D. Highly active anti-retroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann. Intern.Med. 1999, 13, 81-87.
2. Yerly, S.; Kaiser, L.; Race, E.; Bru, J. P.; Clavel, F.; Perrin, L. Transmission of antiretroviral-drug-resistant HIV-1 variants. Lancet 1999, 354, 729-733.
3. Carr, A.; Samaras, C. K.; Thorisdottir, A.; Kaufmann, G. R.; Ghisholm, D. J.; Cooper, D. A. Diagnosis, prediction, and natural course of HIV-1 protease inhibitor associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999, 353, 2093-2099.
4. Carr, A.; Cooper, D. A. Adverse effects of antiviral therapy. Lancet 2000, 356, 1423-1430.
5. Bastard, J.-P.; Caron, M.; Vidal, H.; Jan, V.; Auclair,M.; Vigouroux, C.;Luboinski, J.;Laville,M.;Maachi, M.;Girard, P.-M.; Rozenbaum, W.; Levan, P.; Capeau, J. Association between altered expression of adipogenic factor SREBP1 in lipotrophic adipose tissue from HIV-1 infected patients and abnormal adipocyte differentiation and insulin resistance. Lancet 2002, 359, 1026-1031.
6. Dollé, V.; Fan, E.; Nguyen, C. H.; Aubertin, A. M.; Kirn, A.; Andreola, M. L.; Jamieson, G.; Tarrago-Litvak, L.; Bisagni, E. A new series of pyridinones derivatives as potent non-nucleoside HIV-1 specific reverse transcriptase inhibitors. J. Med. Chem. 1995, 38, 4679-4686.
7. Dollé, V.; Nguyen, C. H.; Legraverend, M.;Aubertin,A.-M.;Kirn, A.; Andreola, M. L.; Ventura, M.; Tarrago-Litvak, L.; Bisagni, E. Synthesis and antiviral activity of 4-benzyl pyridinone derivatives as potent and selective non-nucleoside human immunodeficiency virus type 1 reverse transcriptase inhibitors. J.Med. Chem. 2000, 43, 3949-3962.
8. Benjahad, A.; Courté, K.; Guillemont, J.; Mabire, D.; Coupa, S.; Poncelet, A.; Csoka, I.; Andries, K.; Pauwels, R.; de Béthune, M. P.; Monneret, C.; Bisagni, E.; Nguyen, C. H.; Grierson, D. S. 4-Benzyl and 4-benzoyl-3-dimethylaminopyridin-2(1H)-ones, a new family of potent anti-HIV. Optimization and in Vitro Evaluation against Clinically Important HIV Mutant Strains. J. Med. Chem. 2004, 43, 5501-5514.
9. Benjahad, A.; Croisy, M.; Monneret, C.; Bisagni, E.; Mabire, D.; Coupa, S.; Poncelet, A.; Csoka, I.; Guillemont, J.; Meyer, C.; Andries, K.; Pauwels, R.; de Béthune, M.-P.; Himmel, D. M.; Das, K.; Arnold, E.; Nguyen, C. H.; Grierson, D. S. 4-Benzyl and 4-benzoyl-3-dimethylaminopyridin-2(1H)-ones: In vitro evaluation of new C-3 amino substituted and C-5,6 alkyl substituted analogues against clinically important HIV mutant strains. J. Med. Chem. 2005, 48, 1948-1964.
10. Benjahad, A.; Oumouch, S.; Guillemont, J.; Pasquier, E.; Mabire, D.; Andries, K.; Nguyen, C. H.; Grierson, D.S. Structure - Activity Relationship in the 3-Iodo-4-phenoxypyridinone (IOPY) Series: The Nature of the C-3 Substituent on Anti-HIV Activity. Bioorg. Med. Chem. Lett. 2007, 17, 712-716.
11. Tanaka, H.; Baba, M.; Hayakawa, H.; Sakamaki, T.; Miyasaka, T.; Ubasawa, M.; Takashima, H.; Sekiya, K.; Nitta, I.; Inouye, N.; Shigeta, S.; Walker, R. T.; Balzarini, J.; De Clercq, E. A new class of HIV-1-specific 6-substituted acyclouridine derivatives: synthesis and anti-HIV-1 activity of 5- or 6-substituted analogues of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT). J. Med. Chem. 1991, 34, 349-357.
12. Tanaka, H.; Takashima, H.; Ubasawa,M.; Sekiya, K.; Inouye, N.; Baba, M.; Shigeta, S.; Walker, R. T.; De Clercq, E.; Miyasaka, T. Synthesis and antiviral activity of 6-benzyl analogs of 1-[(2-hydroxyethoxy) methyl]-6-(phenylthio) thymine (HEPT) as potent and selective anti-HIV-1 agents. J. Med. Chem. 1995, 38, 2860-2865.
13. Hopkins, A. L.; Ren, J.; Tanaka, H.; Baba, M.; Okamato, M.; Stuart, D. I.; Stammers, D. K. Design of MKC-442 (Emivirine) analogues with improved activity against drug-resistant HIV mutants. J. Med. Chem. 1999, 42, 4500-14005
14. (a) El-Brollosy, N. R.; Jrgensen, P. T.; Dahan, B.; Boel, A.-M.; Pedersen, E. B.; Nielsen, C. Synthesis of novel N-1 (allyloxymethyl) analogues of MKC-442 (Emivirine) with improved activity against HIV-1 and its mutants. J. Med. Chem. 2002, 45, 5721-5726.
15. (b) Le Van, K.; Cauvin, C.; De Walque, S.; Georges, B.; Boland, S.; Martinelli, V.; Demonté, D.; Durant, F.; Hevesi, L.; Van Lint, C. New pyridinone derivatives as potent HIV-1 nonnucleoside reverse transcriptase inhibitors. J. Med. Chem. 2009, 52, 3636-3643.
16. Himmel, D.M.; Das, K.; Clark, A. D.; Hughes, S. H., Jr.; Benjahad, A.; Oumouch, S.; Guillemont, J.; Coupa, S.; Poncelet, A.; Csoka, I.; Meyer, C.; Andries, K.; Nguyen, C. H.;Grierson, D. S.; Arnold, E. Crystal structures for HIV-1 reverse transcriptase in complexes with three pyridinone derivatives: A new class of non-nucleoside inhibitors effective against a broad range of drug-resistant strains. J.Med.Chem. 2005, 48, 7582-7591.
17. (a) Kappe, T.; Stelzel, H. P.; Ziegler, E. Synthese von Pyridonen aus Enaminen und Cyanessigsauren. Monatsh. Chem. 1983, 114, 953-963.
18. (b) El-Mariah, F. A. A.; Kappe, T. Potential nonsteroidal estrogens and antiestrogens. I. Synthesis of some 7-methoxy-2-(1H)-quinolone derivatives. Croat. Chem. Acta 1986, 59 (1), 171-176.
19. Carr, A.; Cooper, D. A. Adverse effects of antiretroviral therapy. Lancet 2000, 356, 1423.
20. Iversen, A. K.; Shafer, R. W.; Wehrly, K.; Winters, M. A.; Chesebro, B.; Merigan, T. C.; Mullins, J. Multidrug-resistant human immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy. J. Virol. 1996, 70, 1086. (Pubitemid 26029028)
21. Kappe, T. A synthesis of 2-hydroxyquinolizinones-(4). Monatsh. Chem. 1967, 98, 874-886.
22. Soliman, F. S. G.; Kappe, T. Synthesis of 1-cyano-2-hydroxy-4- quinolizinones and corresponding 5-cyano-4-hydroxy-2-pyridones. Part 187: Synthesis of heterocycles. Part 9: Quinolizines and indolizines. Pharmazie 1977, 32 (5), 278-279.
23. Lucas, H. J.; Kennedy, E. R. Iodobenzene dichloride. Org Synth. Coll. 1955, 3, 482.
24. Beck, W.; Kaye, I. A.; Kogon, I. C.; Klein, H. C.; Burlant, W. J. 1-Phenyl-2-(N-methyl-N-benzylamino)ethanol and Related Compounds. J. Org. Chem. 1951, 16 (9), 1434-1441.
25. Jones, R. G.; Ainsworth, C. 1,2,4-Triazole-3-alanine. J. Am. Chem. Soc. 1955, 77 (6), 1538.
26. Francis, J. E.; Gorczyca, L. A.; Mazzenga, G. C.; Meckler, H. A convenient synthesis of 3,5-disubstituted-1,2,4-triazoles. Tetrahedron Lett. 1987, 28 (43), 5133-5136.
27. Browne, E. J.; Polya, J. B. Triazoles. Part VII. Syntheses of substituted 1,2,4-triazoles. J. Chem. Soc. 1962, 5149-5152.
28. Atkinson, M. R.; Polya, J. B. Triazoles. Part III. Mono- and di-methyl(phenyl)-1:2:4-triazoles. J. Chem. Soc. 1954, 3319-3324.
29. Kato, S.; Morie, T.; Hino, K.; Kon, T.; Naruto, S.; Yoshida, N.; Karasawa, T.; Matsumoto, J. Novel benzamides as selective and potent gastric prokinetic agents. 1. Synthesis and structure-activity relationships of N-[(2-morpholinyl)alkyl]benzamides. J. Med. Chem. 1990, 33 (5), 1406-1413.
30. Kawakita, T.; Kuroita, T.; Murozono, T.; Hakira, H.; Haga, K. Benzoic acid compound and use thereof as medicine. PCT Int. Appl. WO 9526953, 1995.
31. Pauwels, R.; Balzarini, J.; Baba, M.; Snoek, R.; Schols, D.; Herdewijn, P.; Desmyter, J.; De Clercq, E. Rapid and automated tetrazolium-based calorimetric assay for the detection of anti-HIV compounds. J. Virol. Methods 1988, 20, 309-321.
32. Hertogs, K.; de Bethune, M. P.; Miller, V.; Ivens, T.; Schel, P.; Van Cauwenberge, A.; Van Den Eynde, C.; Van Gerwen, V.; Azijn, H.; Van Houtte, M.; Peeters, F.; Staszewski, S.; Conant, M.; Bloor, S.; Kemp, S.; Larder, B.; Pauwels, R. A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs. Antimicrob. Agents Chemother. 1998, 42, 269-276.